Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876341 · ClinicalTrials.gov registry record
Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 133
- Enrollment target
NCT02876341: Completed study, sponsored by Rush University Medical Center.
NCT02876341 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 133 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02876341 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 133 participants
- Enrollment target
Study Summary
Retrospective two-cohort study to determine the effect of chronic antihypertensive therapy on new onset atrial fibrillation and clinical outcomes in septic shock.
Primary Outcome
New onset atrial fibrillation defined as atrial fibrillation not present on admission to MICU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-03-31 |
What the finished NCT02876341 record still lists
NCT02876341 is an observational study that tracks outcomes without assigning an intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02876341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02876341 about?
NCT02876341 is a clinical study titled "Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock". Retrospective two-cohort study to determine the effect of chronic antihypertensive therapy on new onset atrial fibrillation and clinical outcomes in septic shock.
What is the current status of trial NCT02876341?
This trial is currently completed. The enrollment target is 133 participants. The study started on 2016-08. Estimated completion is 2017-03-31.
Who is sponsoring clinical trial NCT02876341?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia